Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study

被引：0
|
作者：
Patorno, Elisabetta
Pawar, Ajinkya
Bessette, Lily G.
Najafzadeh, Mehdi
Wexler, Deborah J.
Franklin, Jessica
Deruaz-Luyet, Anouk
Brodovicz, Kimberly
Koeneman, Lisette
Schneeweiss, Sebastian
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-133-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
133-LB
引用
收藏
页数：3
相关论文
共 50 条
  • [41] DPP-4 inhibitors and GLP-1 agonists in type 2 diabetes - early assessment of cardiovascular safety in a nationwide setting
    Mogensen, U. M.
    Andersson, C.
    Fosbol, E. L.
    Schramm, T. K.
    Vaag, A.
    Scheller, N. M.
    Pedersen, C. T.
    Gislason, G.
    Kober, L.
    EUROPEAN HEART JOURNAL, 2013, 34 : 1111 - 1111
  • [42] Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis
    Roddick, A.
    Zheng, S. L.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2471 - 2471
  • [43] SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors and Risk of All-Cause Hospitalization
    Lyu, Beini
    Grams, Morgan
    Chang, Alex R.
    Inker, Lesley A.
    Coresh, Josef
    Shin, Jung-Im
    DIABETES, 2021, 70
  • [44] Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
    Norgaard, Caroline H.
    Starkopf, Liis
    Gerds, Thomas A.
    Vestergaard, Peter
    Bonde, Anders N.
    Fosbol, Emil
    Kober, Lars
    Wong, Nathan D.
    Torp-Pedersen, Christian
    Lee, Christina J-Y
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (06) : 549 - 556
  • [45] Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study
    Htoo, Phyo T.
    Tesfaye, Helen
    Paik, Julie M.
    Wexler, Deborah J.
    Najafzadeh, Mehdi
    Glynn, Robert
    Deruaz-Luyet, Anouk
    Farsani, Soulmaz F. Fazeli
    Koeneman, Lisette
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    DIABETES, 2022, 71
  • [46] Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy
    Takayanagi, Risa
    Uchida, Takumi
    Kimura, Koji
    Yamada, Yasuhiko
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2018, 41 (02) : 153 - 157
  • [47] Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
    Farngren, Johan
    Ahren, Bo
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 99 : 25 - 31
  • [48] DPP-4 Inhibitors and GLP-1 Receptor Agonists for Prevention or Delay of Type 2 Diabetes Mellitus and Associated Complications
    Smith, Dustin K.
    Wessner, Matthew J.
    AMERICAN FAMILY PHYSICIAN, 2018, 97 (07) : 437 - 438
  • [49] SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
    El Mouhayyar, Christopher
    Riachy, Ruba
    Khalil, Abir Bou
    Eid, Asaad
    Azar, Sami
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2020, 2020
  • [50] Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
    Kutz, Alexander
    Kim, Dae Hyun
    Wexler, Deborah J.
    Liu, Jun
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Patorno, Elisabetta
    DIABETES CARE, 2023, 46 (11) : 2004 - 2014
12345